Stock Chat

Join Stock Chat and Discuss this DD Report

We are excited to present Eisai Co., Ltd. (OTC: ESALF).

Full DD Report for ESALF

Recent News from (OTC: ESALF)

Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
TOKYO, Mar 14, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary Eisai China Inc. has launched the gastrointestinal prokinetic agent Cidine in China. Cidine is a gastrointestinal prokinetic agent discovered by Almirall, S.A. Under the terms of a license agree...
Source: ACN Newswire
Date: March, 13 2018 23:16
Eisai (ESALF) Investor Presentation - Slideshow
The following slide deck was published by Eisai Co., Ltd. in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 12 2018 12:14
Merck (MRK) Teams Up With Eisai (ESALY) To Commercialize Cancer Med Lenvima - Slideshow
The following slide deck was published by Eisai Co., Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 08 2018 14:29
Merck teams up with Eisai to commercialize cancer med Lenvima in deal valued as high as $5.76B
Eisai Co. ( OTCPK:ESALF ) inks a collaboration agreement with Merck (NYSE: MRK ) to co-develop and co-commercialize LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor, as monotherapy and in combination with KEYTRUDA (pembrolizumab). More news on: Eisai Co., Ltd....
Source: SeekingAlpha
Date: March, 08 2018 07:46
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
- Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s KEYTRUDA (pembrolizumab) for Multiple Cancer Types - Eisai Books LENVIMA Product Sales and Companies to Share Development and Marketing Costs Equa...
Source: ACN Newswire
Date: March, 08 2018 00:33
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Including First-Ever Phase 3 Head-To-Head Superiority Comparison Versus Zolpidem Er in Patients With Sleep Disorder TOKYO, Mar 8, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Purdue Pharma L.P. today announced positive topline results from multiple studies of lemborexant, an investigational a...
Source: ACN Newswire
Date: March, 07 2018 23:00
Eisai's lemborexant matches Sanofi's extended-release Ambien in late-stage sleep disorder study
Eisai Co. ( OTCPK:ESALF ) and development partner Purdue Pharma L.P. announce positive results from a Phase 3 clinical trial comparing lemborexant to Sanofi's ( SNY +0.4% ) Ambien CR (zolpidem tartrate extended-release) tablets and placebo in patients at least 55 years old with difficu...
Source: SeekingAlpha
Date: March, 07 2018 11:18
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Jointly Developed by Eisai and Saint-Plus TOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has...
Source: ACN Newswire
Date: February, 26 2018 20:33
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
TOKYO, Feb 21, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry, who organizes the Certifi...
Source: ACN Newswire
Date: February, 20 2018 19:25
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Following the issue of the FAD by NICE, lenvatinib will be eligible for reimbursement for this indication via the National Health Service in England (NHS England). TOKYO, Feb 16, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its in-house developed anticancer agent Lenvima (len...
Source: ACN Newswire
Date: February, 15 2018 18:34


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Eisai Co., Ltd. (OTC: ESALF)

Logo for Eisai Co., Ltd. (OTC: ESALF)

Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co. s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.


Contact Information



Current Management

  • Haruo Naito / President, CEO
  • Hideaki Matsui / CFO

Current Share Structure

  • Market Cap: $15,762,530,735 - 03/09/2018
  • Issue and Outstanding: 296,566,900 - 11/30/2011


Daily Technical Chart for (OTC: ESALF)

Daily Technical Chart for (OTC: ESALF)

Stay tuned for daily updates and more on (OTC: ESALF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ESALF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ESALF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ESALF and does not buy, sell, or trade any shares of ESALF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer:



Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us